Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

NCT03647111 · clinicaltrials.gov ↗

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Crizotinib

Sponsor

Hunan Province Tumor Hospital